Ethnic and minority group differences in engagement with COVID-19 vaccination programmes - at Pandemic Pace; when vaccine confidence in mass rollout meets local vaccine hesitancy.
AuthorsReid, John A; orcid: 0000-0002-0073-398X; email: firstname.lastname@example.org
Mabhala, Mzwandile A
MetadataShow full item record
AbstractIsrael, the UK, the USA, and some other wealthier countries lead in the implementation of COVID-19 vaccine mass vaccination programmes. Evidence from these countries indicates that their ethnic minorities could be as disproportionately disadvantaged in COVID-19 vaccines roll-out as they were affected by COVID-19-related serious illnesses. Their disadvantage is linked to their lower social status and fewer social goods compared with dominant population groups.Albeit limited by methodology, early studies attribute lower uptake of COVID-19 amongst ethnic minorities to the wider determinants of vaccine uptake, hesitancy or lack of vaccine confidence, including lower levels of trust and greater concerns about vaccine safety. Early sentinel studies are needed in all early adopter countries.One emerging theme among those of reproductive age in minority communities concerns a worry regarding COVID-19 vaccine's potential adverse effect on fertility. Respected professional groups reassure this is not a credible rationale. Drug and vaccine regulators use understandable, cautious and conditional language in emergency licencing of new gene-based vaccines. Technical assessments on whether there is any potential genotoxicity or reproductive toxicity should be more emphatic.From a public health perspective, sentinel studies should identify such community concerns and act early to produce convincing explanations and evidence. Local public health workforces need to be diverse, multiskilled, and able to engage well with minorities and vulnerable groups. The local Directors of Public Health in the UK are based in each local government area and have a remit and opportunity to stimulate speedy action to increase vaccine uptake.During the rapid Pandemic Pace of the vaccines roll-out, extra efforts to minimise uptake variations are likely to achieve improvements in the next year or two. We expect variations will not disappear however, given that underlying inequalities persist in less inclusive social systems.
CitationIsrael journal of health policy research, volume 10, issue 1, page 33
DescriptionFrom Europe PMC via Jisc Publications Router
History: ppub 2021-05-01, epub 2021-05-27
Publication status: Published
Showing items related by title, author, creator and subject.
Toward ‘Vaccine Internationalism’: The Need for an Equitable and Coordinated Global Vaccination Approach to Effectively Combat COVID-19Wong, Brian L. H.; Green, Manfred S.; Reid, John; Martin-Moreno, Jose M.; Davidovitch, Nadav; Chambaud, Laurent; Leighton, Lore; Sheek-Hussein, Mohamud; Dhonkal, Ranjeet; Otok, Robert; et al. (Frontiers Media S.A., 2021-04-14)
Physicians’ attitudes towards human papillomavirus vaccination programme: A systematic reviewFallows, Stephen; Franco, Maria F. (University of Chester, 2011-12)Human papillomavirus (HPV) vaccine is a newly introduced vaccine against cervical cancer in adolescent girls. Uptake of the vaccine will be dependent on parental acceptability and physician recommendation. To review physicians’ attitudes towards HPV vaccine and identify factors that may influence their intent. Also, to determine if there is any difference in the views of different medical specialties with regards to HPV vaccination. Articles were obtained through computerised searches of CINAHL, Pubmed, Web of Knowledge, Cochrane Library and Science Direct, as well as manual searches in recognised scientific journal. Articles involving physicians’ attitudes, knowledge and behaviour towards HPV vaccine published from 2007 onwards. One reviewer independently assessed relevant studies, risk of bias and data extraction. Twenty nine studies were included in the final review. Twenty four studies used survey for data collection and five studies used interview. Majority of the studies revealed positive view of physicians towards HPV vaccine with high intent to provide vaccination. Barriers identified against HPV vaccination include the following: cost and reimbursement issue; providers concern about vaccine safety; parental concern over vaccine’s safety and efficacy; age is considered too young for vaccination; issue that HPV vaccine could promote sexual activity, recommendation of HPV vaccine from organisations; communication related to sexuality; need for education and other factors like dosing, patient overload, boys should also be vaccinated and parental religious beliefs. No significant difference was noted between specialties with regards to their view about HPV vaccine. Physicians’ role is important in the promotion of HPV vaccine with their high intent and positive attitudes. In order for the HPV vaccination programme to succeed, vaccine should be made available and affordable especially to countries with high incidence of cervical cancer.